PharmaNest

PharmaNest to Present Seven Digital Pathology and AI Communications and Abstracts at the International Liver Congress – EASL 2024, Including Analytical and Clinical Validation Data of Its Digital Biomarker for Fibrosis in Metabolic Associated Steatohepatitis (MASH) Communications will take place at the International Liver Congress – EASL 2024, Milan, Italy, on the following schedule: ·       Wednesday June 5, 2024: (OS-026-YI) Functional role of CD44+ cancer stem cells in intrahepatic cholangiocarcinoma. Dr. Paula Cantallops Vila at Institut d’Investigacions biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain ·       Wednesday June 5, 2024: (WED-262) AI-assisted, quantitative digital pathology-based continuous fibrosis scores perform better than conventional pathology in documenting fibrosis reduction in collaboration with Pr. Vald Ratziu ·       Thursday June 6, 2024: (THU-278) Digital pathology with artificial intelligence analysis provides insight to the efficacy of antifibrotic compounds in human 3D MASH model in collaboration with InSphero AG. ·       Thursday June 6, 2024: (THU-282) Evaluation of performance of a cellular profiling technique for quantification of inflammation and steatosis in liver biopsies of patients with MASH. ·       Thursday June 6, 2024: (THU-298) Evaluation of performance of AI digital pathology on the reproducibility and repeatability of fibrosis phenotyping in MASH liver biopsies ·       Thursday June 6, 2024: (THU-305) Evaluation of the performance of AI digital pathology method (FibroNest) on subsections of biopsies to assess performance variability due to region selection ·       Friday June 7, 2024: (FRI-225) Novel digital pathology adequacy score benchmarks the performance of pre-analytical method for digital pathology and AI end-to-end tissue assays.

Today, as we meticulously refine our five presentations and posters in preparation for the upcoming EASL Congress 2024 conference next week, we extend a warm invitation for you to connect with us. We eagerly look forward to engaging in discussions about your drug discovery and development projects in MASH, Cirrhosis, PBC, PSC and a1ATD. #fibrosis #MASH #EASL2024 #DigitalPathology #PBC #PSC

Today, as we meticulously refine our five presentations and posters in preparation for the upcoming Keystone conference next week, we extend a warm invitation for you to connect with us. We eagerly look forward to engaging in discussions about your research and projects. #FibroNest #OncoNest #CardioNest #DigitalPathology #mash

So proud of our team and collaborators ! Please join me to encourage a new generation of medical scientists using AI platforms.

Alongside with PathAI and HistoIndex, Dr. Mathieu Petitjean presents "FibroNest: single-fiber, Single-cell high content an high resolution digital pathology for the assessment of Liver Biopsies in NASH studies" at the 2024 NASH-TAG conference in Deer Park, UT, USA

We are excited to present PharmaNest's new Logo ! o The head represents the #patients and/or the #pathologists o The digital symbol (#ai ) exists by its own, side by side with the patient and the pathologist. o The non-binary, black facial outline represents our commitment to #diversity o The gradient in the color represents the spectrum of solutions and fibrosis & inflammation Digital Pathology biomarkers generated by the #FibroNest method.

Hi PharmaNest Followers ! We gratefully recognize your presence at our side. Stay in touch! (Mathieu Petitjean, Li Chen, Adi Lightstone, Louis P.,Nathan Aist)

From AASLD 2023: After PharmaNest demonstrated that the span of change of the histological phenotype of fibrosis in the cirrhosis spectrum is as large as from F0 to F3 (EASL2023), our team, in collaboration with the Icahn School of Medicine at Mount Sinai, shows that the automated FibroNest fibrosis digital pathology score can classify F3 from F4 patients and detect changes with a performance that benchmarks histological "manual" methods. - PharmaNest American Association for the Study of Liver Diseases (AASLD) #fibrosis #cirrhosis #fibronest

From AASLD2023:Digital Pathology and AI shows its potential by predicting liver related events in patients with NASH (404 patients with 18 years of follow up). We are not there yet .... but this is super exciting and encouraging for the whole field. We gratefully recognize Pr. Vlad Ratziu who led this wonderful work in behalf of the European HOTSURF consortium. - American Association for the Study of Liver Diseases (AASLD) #fibrosis #digitalpathology #fibronest #TLM2023

Presented at AASLD 2023: The FibroNest AI method describes and quantifies specific histological features of fibrosis regression. While the FALCON 1 NASH F2/F3 study did not meet its primary histological endpoints, we show that pegbelfermin engaged the histological phenotype of Fibrosis, also seen in the circulating biomarkers for fibrosis !! - PharmaNest Bristol Myers Squibb American Association for the Study of Liver Diseases (AASLD) #fibronest #TLM2023